非瓣膜病心房颤动病人华法林抗凝治疗安全性评价

目的:评价非瓣膜病心房颤动(房颤)用华法林抗凝治疗的安全性。方法:选择符合该研究抗凝标准的98例心房颤动病人随机分为两组,华法林治疗组(治疗组)46例,给予华法林3mg/d开始监测凝血酶原时间(PT)及国际标准化比值(INR),7～15天使INR达到2.0～3.0范围内,以后每月查1次INR。若病人增加或减少药物、有出血倾向时随时再测INR。阿司匹林对照组(对照组)52例,给予阿司匹林100mg/d口服2次,密切随访。结果:治疗组9～15d(平均10.1±2.2)INR达2.0～3.0(平均2.25±0.11),其中INR在1.8～2.5(平均1.92±0.23)之间者占90.7%,治疗组未出现脑梗死,而对照组有3例发生脑梗死,两组总不良反应率差异无显著性.。结论:非瓣膜病房颤病人选择华法林3mg/d加强服药后监测及各药物间的相互作用,使INR保持在2.0～3.0之间是有效、安全的。     

阻塞性睡眠呼吸暂停综合征患者肾功能和心钠素的变化分析

目的探讨病人肾功能、心钠素(ANP)的含量变化及经鼻持续气道正压(nCPAP)治疗对阻塞性睡眠呼吸暂停综合征(OSAS)患者的影响。方法选择经多导睡眠图(PSG)确诊为中、重度的OSAS患者11例为试验组,PSG检查正常者14例为对照组，试验组给予nCPAP治疗，分别测定其血尿肌酐、尿量、尿β2-微球蛋白(β2-MG)、血浆心钠素(ANP)，并计算出内生肌酐清除率(Ccr)，比较试验组与对照组及试验组治疗前后各项指标的差异。结果试验组与对照组比较，Ccr,尿β2-MG差异无显著性，经nCPAP治疗后两指标也无明显改变；试验组的夜尿量、血ANP含量显著高于对照组，nCPAP治疗后上述指标均较治疗前明显下降。结论OSAS患者夜尿量增多可能与ANP增加有关，这种增高可以被nCPAP治疗所纠正。     

重度烧伤患者休克期血浆B型钠尿肽含量变化及意义

Objective To study the plasma content of B-type natriuretic peptide (BNP) in patients with severe burn during shock stage and probe its clinical significance. Methods Forty-two patients aged 18-60 years, with total burn surface area ≥30%TBSA or full-thickness burn area ≥10% TBSA, hospital-ized within 4 hours after burn, were divided into A group (with total burn surface area 30% -50% TBSA or full-thickness burn area 10% -20% TBSA, n = 21 ), and B group (with total burn surface area 50% TB-SA or full-thickness burn area > 20% TBSA, n = 21 ). Twenty patients admitted during the same time for plastic surgery were enrolled as control group. The plasma levels of BNP, creatine kinase (CK), CK-MB, troponin I (Tnl) of all patients were determined on admission. The levels of BNP, Tnl and fluid resuscita-tion volume were examined at 8, 16, 24, 48 post burn hour (PBH) in A and B groups. Analysis of correla-tion between BNP and fluid resuscitation volume was performed. Results On admission: BNP level in A group (68±19 ng/L) and B group (99±38 ng/L) , respectively, was increased as compared with that in control group (17±7 ng/L, P <0.01 ). Tnl level in A group (2.13±0.67 μg/L) and B group (2.98± 0.58μg/L), respectively, was increased as compared with that in control group (0.12 ± 0.03 μg/L, P < 0.01). There was no obvious difference in CK, CK-MB levels among A, B, and control groups ( P > 0.05). BNP levels in A, B groups continuously rose during 8 - 48 PBH, and they were positively correlated with fluid resuscitation volume. TnI level peaked at 24 PBH, and decreased at 48 PBH. Conclusions The plasma level of BNP is sensitive to reflect changes in myocardial ischemia and hypoxia as a rise in level of TnI in shock stage of severe burn, and it was positively correlated with fluid resuscitation volume. BNP can be used to guide fluid resuscitation during shock stage.     

Identification of the C-terminal flanking peptide of preprocholecystokinin in rat brain by a novel radioimmunoassay

The C-terminal flanking peptide of preprocholecystokinin (preproCCK) has been identified in extracts of rat brain using a novel radioimmunoassay. There is a single form of immunoreactive material on gel filtration, ion exchange and reversed-phase HPLC. The C-terminal preproCCK immunoreactivity had a similar pattern of distribution to CCK8 in different regions of rat brain. This assay should help in studies of neuronal CCK biosynthesis.     

老年心功能不全血浆心钠素浓度的变化

采用放射免疫法测定31例老年心功能不全患者血浆心钠素(ANP)浓度,发现老年心功能不全组ANP明显低于对照组(P<0.01)。血浆ANP含量随心功能不全的严重程度而明显减少(P<0.05)。病程与ANP浓度呈负相关 (r=-0.441,P<0.05)。不同病种、不同受累部位及有或无房颤之间ANP差异无显著性(P<0.05)。     

多价精子抗原表位肽的设计与免疫效应研究

目的 开发可供两性使用的多价合成嵌合肽疫苗。方法 选择小鼠精子／睾丸特异性抗原SP17、Cyritestin中特异性氨基酸序列与牛核糖核酸酶非限制性T细胞表位作为骨架，按一定连接方式设计、合成新抗原35肽，并与弗氏佐剂混悬后免疫雌性BALB／C小鼠。结果 在430A固相自动肽合成仪上成功地合成35肽，并经HPLC纯化、质谱鉴定证实其纯度达95％以上；免疫后小鼠血清特异性IgG抗体滴度最高达1：6000，阴道粘膜冲洗液中特异性IgA抗体滴度最高达1：300；小鼠脾脏淋巴细胞增殖率达50％左右，淋巴细胞分泌的INF－γ和IL－4分别为60、108μg/ml；实验组BALB／c雌鼠妊娠率平均降至60％，每胎产仔数平均降低58％－71％。结论 含有两种特异性精子抗原中特异性氨基酸序列的新抗原可激发小鼠产生较理想的特异性体液免疫和粘膜免疫，并使小鼠受孕率下降，为研制适宜于两性的多价抗生育疫苗提供了实验基础。     

Pharmacokinetics of peptide T in patients with Acquired Immunodeficiency Syndrome (AIDS)

1. The pharmacokinetics of Dalal-peptide T-NH2 (peptide T) was determined during phase I clinical trials in patients with acquired immunodeficiecy disease (AIDS) and AIDS related complex (ARC). Drug levels were determined by specific RIA, and in some cases with HPLC analysis, after intraveneous (i.v.) or intranasal (i.n.), via metered sprayer, administration.

2. The plasma kinetics appeared to be bi-phasic with a first compartment half-life of 30 to 60 minutes and a second plasma clearence rate of 4 to 6 hours, observed for both routes of administration. Peptide T, in one individual was confirmed to be present at 6 hrs in plasma, determined after HPLC isolation followed by specific RIA.

3. Bioavailabilty, determined for a 2 mg test dose in six individuals was 9.3 ± 6.9 nmol/L. Peak plasma levels of 41 ± 30 nmol/L after 10 mg i.n., 2.8 ± 5.9 nmol/L after 2mg i.n., and 0.13 ± 0.07 nmol/L after 0.4 mg i.n. were observed. In two individuals tested, peptide T was detected in CSF at levels 20% of the corresponding plasma level 90 and 145 minutes post i.v. administration. Peptide T was not detected in urine. I.N. administration was well tolerated for times up to 21 months.     

Two-dimensional echocardiography in the diagnosis of intracardiac masses: A prospective study with anatomic validation

The accuracy of two-dimensional echocardiography in the detection of intracardiac masses was verified in 334 patients who underwent cardiac catheterization in our laboratory over 21 consecutive months. A complete two-dimensional echocardiographic (2DE) examination was performed a day before catheterization. The presence or absence of a mass was verified at surgery in 77 patients who successively underwent mitral or aortic valve replacement (51), left ventricular aneurysmectomy with or without myocardial revascularization (25), and resection of atrial myxoma (2). In 32 patients 2DE revealed the presence of a mass-left or right atrial thrombi in 12, left atrial myxoma in 2, left ventricular thrombi in 16, and endocardial vegetations in 2. The other 45 patients were free of intracardiac masses on 2DE. Anatomic verification at surgery revealed the presence of an intracardiac mass in 34 patients. In 30 (true positives) of these, 2DE revealed the mass as well, and in 4 (false negatives) the presence of a mass had not been identified by 2DE. In 2 patients (false positives) the predicted mass was not found at surgery. Absence of a mass was correctly predicted by 2DE in 41 patients (true negatives). Thus 2DE detected intracardiac masses with sensitivity of 88.2% and a specificity of 95.3%. We recommend that 2DE be performed in all patients prior to hemodynamic study and/or cardiac surgery to enable safer management of patients with intracardiac masses during cardiac catheterization and/or cardiac surgery.     

Two-step hard acid deprotection/cleavage procedure for solid phase peptide synthesis

A new two-step deprotection/cleavage procedure for t-butoxycarbonyl (Boc) based solid phase peptide synthesis is reported. First the protective groups are removed from 4-(oxymethyl)-phenylacetamidomethyl (PAM) resin attached peptide with the weak hard acid, trimethylsilyl bromide-thioanisole/trifluoroacetic acid (TFA). In the second step, the peptide is cleaved from the resin with a stronger hard acid such as trimethylsilvl trifluoromethanesulfonate in TFA or with HF. The method is also shown to deformylate Nⁱⁿ-formyltryptophan moiety efficiently. The usefulness of this procedure for practical solid phase peptide synthesis is demonstrated by comparison with other deprotection methods in the synthesis of urotensin II and human endothelin.     

Co-localization of SCPB-like and FMRFamide-like immunoreactivities in crustacean nervous systems

A monoclonal antibody to the molluscan small cardioactive peptide SCPB and a polyclonal antibody to FMRFamide were used to localize antigens in the stomatogastric nervous system and brain of two species of Cancer. Both antibodies labeled cell bodies, axons, and neuropilar processes in the brain and in the stomatogastric nervous system. All of the SCPB immunoreactive neurons were co-labeled with antibody to FMRFamide. However, antibody to FMRFamide labeled additional neurons of the commissural ganglion and the brain that were not immunoreactive to the monoclonal SCPB antibody.